The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
== Causes == The syndrome often occurs once children have moved away, and a partner has died or is dying. An elderly person with nobody left to cook for, or without the skills to cook, will revert to a diet of simple foods such as bread, cheese and crackers, and canned foods. While the sodium content is variable in such foods, they are among the top contributors of sodium in the average American's diet. However, if portion sizes are inadequate, a person may not be consuming enough protein and salt. When combined with excessive water intake, this results in insufficient solute concentration. Patients with poor kidney function, or low glomerular filtration rate, are at even higher risk of hyponatremia due to increased water retention. According to the New York Times, as many as 60% of seniors living at home are either malnourished or at risk of becoming malnourished. In addition to the problems that a lack of nutrients will cause, this state also means that the complications of other illnesses, even the common cold, can be much more severe. Factors that lead to the syndrome include poverty, social isolation, psychological issues such as depression, loss of taste and smell, chronic illnesses that cause a lack of appetite, dental problems that result in difficulty chewing and swallowing foods, a decline in cognitive functioning, alcoholism, and physical disabilities and limitations. Though less of a factor than psychological issues, the increased number of medications often taken by elderly people can also affect eating habits.
Austin debuted in World Championship Wrestling in May 1991. He was nicknamed "Stunning" Steve Austin, a name and gimmick he later said he could not commit to. Austin was originally paired with a valet named Vivacious Veronica but was later joined by Jeannie Adams, known as "Lady Blossom". Just weeks after his debut, Austin defeated Bobby Eaton for his first WCW World Television Championship on June 3, and later that year joined Paul E. Dangerously's Dangerous Alliance. Austin lost the WCW World Television Championship to Barry Windham in a two-out-of-three-falls match on April 27, but regained the championship from Windham the following month. He enjoyed a second lengthy reign as champion, before losing the championship to Ricky Steamboat at Clash of the Champions XX in September 1992, while the Dangerous Alliance disbanded shortly thereafter. In August and September 1992, as part of a working agreement between WCW and New Japan Pro-Wrestling (NJPW), Austin wrestled four matches in Japan. He took part in the 1992 G1 Climax, defeating Arn Anderson in the first round before losing to Keiji Muto in the second round. He and Arn Anderson then defeated Raging Staff (Super Strong Machine and Tatsutoshi Goto) in a tag team bout held in the Ryōgoku Kokugikan in Tokyo. In his final bout, Austin challenged Masahiro Chono for the NWA World Heavyweight Championship in the main event of the "Battle Hold Arena" event at the Yokohama Arena, losing by submission after Chono applied an STF.
=== Other locations === Every Halloween since 1969, a pumpkin has been impaled onto the spire of North Miami Public Library by a group named Coxie's Army. This has become a celebrated tradition, and is often accompanied by the hanging of a poem at the library's entrance. At the University of Montana, a pumpkin has been placed on the spire of the Main Hall every October since 1995. These pranks resulted in arrests on charges of trespassing in 2004 and 2016.
The two substrates of this enzyme are (S)-dihydroorotic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are orotic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-dihydroorotate:NAD+ oxidoreductase. This enzyme is also called orotate reductase (NADH). This enzyme participates in pyrimidine metabolism. It has 2 cofactors: flavin adenine dinucleotide, and flavin mononucleotide.
The addition of the cyano group generally increases the potency. Therefore, researchers' attention was directed to those compounds. Usually, DPP-4 inhibitors are either substrate-like or non-substrate-like.
Sources: en.wikipedia.org
== Operation == In an ion-to-photon detector, a photomultiplier tube is coated with a layer of scintillator compound, such as Rhodamine B or CsI. When the ions pass through the mass analyzer of the spectrometer, they strike the scintillator compound and cause the release of photons. These photons are then detected by the photomultiplier tube. A conversion dynode, such as a microchannel plate can also be used between the ion beam and the scintillator to increase the signal. An MCP, when struck by an ion, will release electrons which then strike the scintillator.
By the early 2000s most lichen phylogenies analysed 3–5 genes (a few thousand base pairs in total). Frequently used loci were nuLSU rDNA, ITS (the standard barcode), and protein-coding fragments such as RPB1/2 or β-tubulin. Multilocus trees clarified family- and order-level relationships. They confirmed that almost all lichen-forming ascomycetes fall into three classes: Lecanoromycetes (the largest, e.g., Parmeliaceae, Lecanoraceae, Physciaceae), Eurotiomycetes (e.g., some Verrucaria), and Sordariomycetes (e.g., Graphidaceae). A small minority occur in the Basidiomycota (several agaric and clavarioid orders) or in smaller ascomycete classes. Thus molecular work placed lichens securely within the fungal tree, as Santesson had anticipated. The results prompted extensive revision; orders and families were reorganized to remove polyphyletic groups. For example, the pre-molecular 'Lecanorales' was divided into several orders (Lecanorales, Peltigerales, Teloschistales, etc.) after DNA data showed that superficially similar fruiting bodies did not imply close relationship. By the late 2000s a molecular phylogeny was routine in new taxonomic studies. Traditional methods remained important alongside molecular approaches. Morphology and chemistry remained essential: they guided sampling, framed hypotheses, and provided the diagnostic traits needed to circumscribe taxa. Many new species—particularly from biodiversity-rich regions—were still described from morphology alone or with a single DNA barcode.
The atmospheres of Mars, Mercury and Titan (the largest moon of Saturn) contain argon, predominantly as 40Ar. The predominance of radiogenic 40Ar is the reason the standard atomic weight of terrestrial argon is greater than that of the next element, potassium, a fact that was puzzling when argon was discovered. Mendeleev positioned the elements on his periodic table in order of atomic weight, but the inertness of argon suggested a placement before the reactive alkali metal. Henry Moseley later solved this problem by showing that the periodic table is actually arranged in order of atomic number (see History of the periodic table).
== Research == Metformin is a pleiotropic drug, with extensive off-target activity beyond its antidiabetic effect. Much of this has been attributed to its action on AMP-activated protein kinase (AMPK), although other mechanisms have been proposed. Metformin has been studied for its effects on multiple other conditions, including:
Lysergic acid, or lysergate, also known as D-lysergic acid and (+)-lysergic acid, is a precursor for a wide range of ergoline alkaloids that are produced by the ergot fungus and found in the seeds of Argyreia nervosa (Hawaiian baby woodrose), and Ipomoea species (morning glories, ololiuhqui, tlitliltzin). Amides of lysergic acid, lysergamides, are widely used as pharmaceuticals and as psychedelic drugs, e.g. lysergic acid diethylamide (LSD). Lysergic acid is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The name "lysergic acid" comes from the fact that it is a carboxylic acid, and it was first made by hydrolysis of various ergot alkaloids.
Sources: en.wikipedia.org
Afropop Worldwide's public radio program on Zulu Music, "The Zulu Factor" People of Africa, Zulu marriage explained An article on Piet Retief, including his interactions with Dingane History section of the official page for the Zululand region Archived 26 September 2008 at the Wayback Machine Human Rights Watch report on KwaZulu, just before the 1994 elections – This includes detailed, well-referenced, sections on recent Zulu history.
Purification in a chemical context is the physical separation of a chemical substance of interest from foreign or contaminating substances. Pure results of a successful purification process are termed isolate. The following list of chemical purification methods should not be considered exhaustive.
Silica gel is a chemically inert, non-toxic, polar, and dimensionally stable (< 400 °C or 750 °F) amorphous form of SiO2. It is prepared by the reaction between sodium silicate and acetic acid, which is followed by a series of after-treatment processes such as aging, pickling, etc. These after-treatment methods results in various pore size distributions. Silica is used for drying of process air (e.g. oxygen, natural gas) and adsorption of heavy (polar) hydrocarbons from natural gas.
Odr-4 GPCR localization factor homolog, also known as C1orf27, is a protein in humans, encoded by the ODR4 gene. It is accession number NM_017847. This is a membrane protein that is 3926 base pairs long with the most extensive string of amino acids being 454aa long. C1orf27 exhibits cytoplasmic expression in epidermal tissues. Predicted associated biological processes of the gene include cell fate specification and developmental properties.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.